245 related articles for article (PubMed ID: 16687991)
1. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation.
Grant JE; Potenza MN
Int Clin Psychopharmacol; 2006 Jul; 21(4):203-9. PubMed ID: 16687991
[TBL] [Abstract][Full Text] [Related]
2. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation.
Koran LM; Chuong HW; Bullock KD; Smith SC
J Clin Psychiatry; 2003 Jul; 64(7):793-8. PubMed ID: 12934980
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
4. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase.
Dell'Osso B; Hadley S; Allen A; Baker B; Chaplin WF; Hollander E
J Clin Psychiatry; 2008 Mar; 69(3):452-6. PubMed ID: 18312057
[TBL] [Abstract][Full Text] [Related]
6. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
Davidson JR; Bose A; Korotzer A; Zheng H
Depress Anxiety; 2004; 19(4):234-40. PubMed ID: 15274172
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
8. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
9. An open-label trial of escitalopram in the treatment of pathological gambling.
Black DW; Shaw M; Forbush KT; Allen J
Clin Neuropharmacol; 2007; 30(4):206-12. PubMed ID: 17762317
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
Davidson JR; Bose A; Wang Q
J Clin Psychiatry; 2005 Nov; 66(11):1441-6. PubMed ID: 16420082
[TBL] [Abstract][Full Text] [Related]
11. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
Pollack M; Kinrys G; Krystal A; McCall WV; Roth T; Schaefer K; Rubens R; Roach J; Huang H; Krishnan R
Arch Gen Psychiatry; 2008 May; 65(5):551-62. PubMed ID: 18458207
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
Stahl SM; Gergel I; Li D
J Clin Psychiatry; 2003 Nov; 64(11):1322-7. PubMed ID: 14658946
[TBL] [Abstract][Full Text] [Related]
13. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
[TBL] [Abstract][Full Text] [Related]
14. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.
Grant JE; Kim SW; Odlaug BL
Biol Psychiatry; 2007 Sep; 62(6):652-7. PubMed ID: 17445781
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.
Grant JE; Kim SW; Hartman BK
J Clin Psychiatry; 2008 May; 69(5):783-9. PubMed ID: 18384246
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
17. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.
Montgomery SA; Nil R; Dürr-Pal N; Loft H; Boulenger JP
J Clin Psychiatry; 2005 Oct; 66(10):1270-8. PubMed ID: 16259540
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
Mohamed S; Osatuke K; Aslam M; Kasckow J
Am J Geriatr Pharmacother; 2006 Sep; 4(3):201-9. PubMed ID: 17062320
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation.
Koran LM; Aboujaoude EN; Gamel NN
J Clin Psychiatry; 2007 Mar; 68(3):422-7. PubMed ID: 17388713
[TBL] [Abstract][Full Text] [Related]
20. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
